X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (1) 1
adult (1) 1
aged (1) 1
aged, 80 and over (1) 1
analysis (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacokinetics (1) 1
antibody-drug conjugate (1) 1
antibody-drug conjugates (1) 1
antibody‐drug conjugate (1) 1
antigens (1) 1
antigens, neoplasm - metabolism (1) 1
antineoplastic agents, phytogenic - administration & dosage (1) 1
antineoplastic agents, phytogenic - adverse effects (1) 1
antineoplastic agents, phytogenic - pharmacokinetics (1) 1
breast cancer (1) 1
breast-cancer (1) 1
camptothecin (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - adverse effects (1) 1
camptothecin - analogs & derivatives (1) 1
camptothecin - blood (1) 1
camptothecin - pharmacokinetics (1) 1
cancer (1) 1
care and treatment (1) 1
cell adhesion molecules - metabolism (1) 1
cell surface (1) 1
clinical pharmacokinetics (1) 1
clinical trial (1) 1
colorectal-cancer (1) 1
criteria (1) 1
drug dosages (1) 1
epithelial cancers (1) 1
epithelial tumors (1) 1
etirinotecan pegol nktr-102 (1) 1
ezn-2208 (1) 1
female (1) 1
glucuronosyltransferase (1) 1
glucuronosyltransferase - genetics (1) 1
half life (1) 1
half-life (1) 1
humans (1) 1
immu-132 (1) 1
immunoconjugates - administration & dosage (1) 1
immunoconjugates - adverse effects (1) 1
immunoconjugates - pharmacokinetics (1) 1
immunoglobulin g (1) 1
immunoglobulin g - metabolism (1) 1
immu‐132 (1) 1
index medicus (1) 1
irinotecan (1) 1
male (1) 1
metabolites (1) 1
metastases (1) 1
metastasis (1) 1
middle aged (1) 1
neoplasms - drug therapy (1) 1
neoplasms - metabolism (1) 1
neutropenia (1) 1
neutropenia - chemically induced (1) 1
oncology (1) 1
patients (1) 1
pharmacokinetics (1) 1
pharmacology (1) 1
radioactive half-life (1) 1
response evaluation criteria in solid tumors (1) 1
safety (1) 1
safety and security measures (1) 1
sn-38 (1) 1
sn‐38 (1) 1
solid tumors (1) 1
therapeutic target (1) 1
time factors (1) 1
toxicity (1) 1
trophoblastic cell-surface antigen (1) 1
trophoblastic cellsurface antigen (1) 1
trophoblastic cell‐surface antigen (1) 1
tumors (1) 1
uridine (1) 1
usage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3843 - 3854
BACKGROUND Sacituzumab govitecan (IMMU‐132), an antitrophoblastic cell‐surface antigen (anti‐Trop‐2) humanized antibody‐SN‐38 conjugate, had encouraging... 
clinical trial | trophoblastic cell‐surface antigen (Trop‐2) | epithelial cancers | antibody‐drug conjugate | IMMU‐132 (sacituzumab govitecan) | SN‐38 | trophoblastic cell-surface antigen (Trop-2) | SN-38 | antibody-drug conjugate | IMMU-132 (sacituzumab govitecan) | METABOLITES | SOLID TUMORS | ETIRINOTECAN PEGOL NKTR-102 | CLINICAL PHARMACOKINETICS | BREAST-CANCER | EZN-2208 | ONCOLOGY | COLORECTAL-CANCER | THERAPEUTIC TARGET | IRINOTECAN | trophoblastic cellsurface antigen (Trop-2) | Neoplasms - metabolism | Humans | Middle Aged | Half-Life | Immunoconjugates - pharmacokinetics | Male | Response Evaluation Criteria in Solid Tumors | Immunoconjugates - administration & dosage | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Camptothecin - blood | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Irinotecan | Aged | Immunoglobulin G - metabolism | Usage | Care and treatment | Safety and security measures | Analysis | Epithelial tumors | Pharmacokinetics | Antibody-drug conjugates | Camptothecin | Antigens | Toxicity | Immunoglobulin G | Radioactive half-life | Breast cancer | Pharmacology | Metastasis | Criteria | Patients | Cell surface | Metastases | Uridine | Safety | Solid tumors | Drug dosages | Cancer | Tumors | Half life | Neutropenia | Glucuronosyltransferase | Index Medicus | Abridged Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.